Research study Program year 2025 Source: CMS Open Payments

Pmcs-011

Research payments

$478,000

65 payments

Through program year 2025, $478,000 in research payments was reported against Pmcs-011, across 65 payments, paid by RxSight Inc.

Paid by: RxSight Inc
ClinicalTrials.gov: No trial number was reported for this study

By program year

2 rows

Year	Kind	Amount	Payments
2025	Research	$414,000	51
2024	Research	$64,000	14

Breakdown

Who paid Research payments · program years 2024–2025

RxSight Inc $478,000 65 payments

Who received the money Research payments · program years 2024–2025

Berkeley Eye Center Organisation paid for research $114,000 11 payments
Collins Vision Organisation paid for research $108,000 11 payments
Laser Eye Center Of Silicon Valley Organisation paid for research $60,000 6 payments
Lee Katzman LLC Organisation paid for research $54,000 6 payments
Clarity Eye Center Pllc Organisation paid for research $26,000 1 payment
Silk Vision And Surgical Center Organisation paid for research $20,000 7 payments
Digaetano Cataract Services Organisation paid for research $16,000 2 payments
Eye Associates Of Central Texas Organisation paid for research $12,000 2 payments
Marr-Kirkland Eye Center Organisation paid for research $12,000 2 payments
Highland Clinic Apmc-Ap Organisation paid for research $12,000 2 payments

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

7 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.